KENALOG is a licensed trademark of Bristol-Myers Squibb Company.
KENALOG (triamcinolone acetonide topical aerosol, USP) Spray is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
• |
Contraindications: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations. |
• |
Precautions: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. |
• |
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface area, prolonged use, and the addition of occlusive dressings. |
• |
Patients receiving a large dose of any topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression. |
• |
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. |
• |
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. |
• |
Caution should be exercised when topical corticosteroids are administered to a nursing woman. |
• |
This preparation is not for ophthalmic, oral, or intravaginal use. |
• |
For topical use only. |
Reference: 1. National Psoriasis Foundation. Topical steroids potency chart. https://www.psoriasis.org/about-psoriasis/treatments/topicals/steroids/potency-chart. Updated 2016. Accessed March 28, 2018.
